ESR1 and breast cancer: The current results demonstrated that BC had a CCKBR/p-ERK/p-P65-negative molecular subtype which corresponded to ER+, indicating that clinical trials targeting ERK1/2 could have been based on incorrect assumptions due to the complexity of ERK context.